drugset
drugset / Trial / NCT01396252

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

NCT01396252 ↗

Phase 1 Completed 57 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-820836 in healthy Japanese subjects and Japanese patients with depression.

Timeline

Start
2011-09
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Liafensine Small molecule 0.5 mg Oral
Subject Liafensine Small molecule 1 mg Oral
Subject Liafensine Small molecule 2 mg Oral

Indications

depressive disorder